Adaptimmune Therapeutics Q3 EPS $(0.06) Beats $(0.31) Estimate, Sales $237K Miss $1.48M Estimate

Adaptimmune Therapeutics (NASDAQ:ADAP) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.31) by 80.65 percent. This is a 700 percent decrease over earnings of $0.01 per share

Benzinga · 11/06/2019 12:37

Adaptimmune Therapeutics (NASDAQ:ADAP) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.31) by 80.65 percent. This is a 700 percent decrease over earnings of $0.01 per share from the same period last year. The company reported quarterly sales of $237 thousand which missed the analyst consensus estimate of $1.48 million by 83.99 percent. This is a 99.42 percent decrease over sales of $40.792 million the same period last year.